RT Journal Article
T1 Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
A1 Chantada Vázquez, María del Pilar
A1 Conde Amboage, Mercedes
A1 Graña López, Lucía
A1 Vázquez Estévez, Sergio
A1 Bravo López, Susana Belén
A1 Núñez González, Cristina
K1 Breast cancer
K1 HER2-positive
K1 Neoadjuvant
K1 Predictive
K1 Biomarkers
K1 Proteomics
AB Despite the increasing use of neoadjuvant chemotherapy (NAC) in HER2-positive breast cancer (BC) patients, the clinical problem of predicting individual treatment response remains unanswered. Furthermore, the use of ineffective chemotherapeutic regimens should be avoided.Serum biomarker levels are being studied more and more for their ability to predict therapy response and aid in the development of personalized treatment regimens. This study aims to identify effective protein networks and biomarkers to predict response to NAC in HER2-positive BC patients through an exhaustive large-scale LC-MS/MS-based qualitative and quantitative proteomic profiling of serum samples from responders and non-responders. Serum samples from HER2-positive BC patients were collected before NAC and were processed by three methods (with and without nanoparticles).The qualitative analysis revealed differences in the proteomic profiles between responders and non-responders, mainly in proteins implicated in the complement and coagulation cascades and apolipoproteins. Qualitative analysis confirmed that three proteins (AFM, SERPINA1, APOD) were correlated with NAC resistance. In this study, we show that serum biomarker profiles can predict treatment response and outcome in the neoadjuvant setting. If these findings are further developed, they will be of significant clinical utility in the design of treatment regimens for individual BC patients.
PB MDPI
SN 2072-6694
YR 2022
FD 2022
LK http://hdl.handle.net/10347/33410
UL http://hdl.handle.net/10347/33410
LA eng
NO Chantada-Vázquez, M. D. P., Conde-Amboage, M., Graña-López, L., Vázquez-Estévez, S., Bravo, S. B., & Núñez, C. (2022). Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Cancers, 14(4).
NO This research was funded by Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (FEDER), grant number CP16/00139 and Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), grant number IN607D 2021/02. M. Conde-Amboage acknowledge the financial support of Grant PID2020-116587GB-I00 funded by MCIN/AEI/10.13039/501100011033 and the European Union.
DS Minerva
RD 3 may 2026